



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
02.09.1998 Bulletin 1998/36

(51) Int. Cl.⁶: **A61K 39/12, C12N 7/08,**
A61K 35/76

(21) Application number: **97200298.4**

(22) Date of filing: **03.02.1997**

(84) Designated Contracting States:
NL

(71) Applicant: **DIMMINACO AG/SA/LTD.**
8134 Adliswil (CH)

(72) Inventor:
**The designation of the inventor has not yet been
filed**

(74) Representative:
Wileman, David Francis, Dr. et al
c/o Wyeth Laboratories
Huntercombe Lane South
Taplow Maidenhead Berkshire SL6 OPH (GB)

(54) **Infectious bursitis vaccine**

(57) The present invention is concerned with a vaccine which is capable of protecting poultry against Infectious Bursitis infections, characterized in that it contains an Infectious Bursitis virus which has the combined properties of upon administration to a chicken causing a reduction in the size of the bursal size, expressed as bursa/body weight ratio, of less than 55 % and the capability to protect poultry having an ELISA antibody titer of at least about 500 and with viruses having the above characteristics.

Description

The present invention is concerned with a vaccine which is capable of protecting poultry against Infectious Bursitis infections, and with novel viruses useful for preparing such vaccines.

Infectious Bursitis is an infective disease which can afflict poultry and which is caused by the Infectious Bursal Disease Virus (IBDV). The agent of Infectious Bursitis belongs to the family Birnaviridae, genus Birnavirus and affects primarily the Bursa of Fabricius. This causes an atrophy of the Bursa. Infection with the virulent viruses found in the field generally causes reduction of the bursa weight to approximately one-third of the normal weight. This is normally expressed as the bursa/body weight ratio (BBR). The disease gives degeneration and necrosis of the B lymphocyte population of the bursa. This may result in immunosuppression. The degree of atrophy (and subsequent degeneration) of the bursa depends on the virulence of the strain involved.

Serologically IBDV can be distinguished into two different types: type 1 is found in chickens, whereas type 2 is found in turkeys.

Prevention of Infectious Bursitis is based on vaccination.

The vaccine strains currently in use are divided into highly virulent (= intermediate plus; examples: Bursine Plus, Bursine 3), intermediate virulent (e.g. Bursine 2, D78, LZ228TC) and highly attenuated mild (= avirulent; e.g. Bursine 1) strains.

Highly virulent, intermediate and avirulent strains break through maternal virus-neutralizing antibody levels of 1:500, 1:250 or less than 1:100, respectively ("Diseases of Poultry", ninth edition, ed: Calnek et al.; Iowa State University Press, 1991, p. 659). Using the ELISA system to monitor maternal antibodies, comparable results are obtained. The virulent (intermediate plus) vaccines break through IDDEX-ELISA titers of about 500. Intermediate and mild strains are found to break through much lower titers to induce a seroresponse.

The virulence of strains is monitored by the effect on the bursa weight (BBR) as described earlier, or by the microscopical changes. The following table (TABLE 1) shows the level of virulence of intermediate plus vaccines (Poultvac Bursa Plus, Delvax LZ228E) and of virulent field virus (isolate D6948E) on the Bursa weight (expressed as percentage BBR as compared to normal).

TABLE 1

strain / vaccine	BBR 3 w. after inoculation (% of controls)
Poultvac Bursa Plus	27
Delvax LZ228E	39
D6948E 10a89	27
D6948E 10a89	39
mean	33

As a consequence of the above practitioners who wish to vaccinate young chickens with high maternal antibody titers have to accept the negative consequences of the more "hot" strains (such as severe trachea lesions and a high death rate) as well.

Hence, there is a need for a vaccine which is less virulent, but which is able to break through high maternal antibody titers at the same time.

Surprisingly, IBDV with this set of characteristics has been found. Therefore the present invention is concerned with a vaccine which is capable of protecting poultry against Infectious Bursitis infections, characterized in that it contains an Infectious Bursal Disease virus which has the combined properties of an intermediate virulence and the capability to protect poultry with an ELISA antibody titer of at least about 500.

As a particular example of this new class of viruses has been isolated the IBDV strain internally indicated as strain 9793, and a sample of which has been deposited at the Collection Nationale de Cultures de Microorganismes of Institut Pasteur at Paris (France) under No. 1-1810 on January 22, 1997.

The vaccine virus is prepared from Seed virus by one or more passages on a suitable medium. Preferably, all vaccine virus is derived from a single stock virus pool - the Master Seed virus. Optionally a Working Seed Virus pool is prepared from this Master Seed by one or more passages, and the actual vaccine virus is prepared from this Working Seed by one or more passages as well.

Suitable media for passaging during these respective propagation steps from Master Seed to vaccine virus are for example Specific Pathogen Free (SPF) eggs, Specific Antibody Negative (SAN) eggs, primary chicken cells or an avian

cell line.

The vaccine according to the present invention preferably contains live viruses of the new IBDV class described above. The effective dose per chicken can vary between about 10^2 and about 10^6 EID₅₀, preferably between about 10^3 and 10^5 EID₅₀. The vaccine can be administered safely to one-day-old chicken and in ovo.

5 The vaccine according to the present invention based on live IBDV preferably is shipped in freeze-dried form and dissolved in water prior to use.

The IBDV vaccine according to the present invention preferably is administered by the enteral route, e.g. orally (in the drinking water or individually by pipette), oculonasally or by spray.

The IBDV strain 9793 has the following characteristics:

10 Induces antibody in birds with a maternal antibody level ≥ 500 (measured by IDDEX ELISA). This is normally only possible with so called "hot" vaccines and/or virulent field strains. Those hot vaccines and field strains will affect the Bursa of Fabricius very much causing a depletion of B lymphocytes.

Strain 9793 is much less damaging to the bursa as measured by the size of the bursa after infection.

15 EXAMPLE 1

Preparation of the vaccine

Preparation of the Working Seed.

20

One vial of the Master Seed Virus of strain 9793 was resuspended in 1.0 ml of distilled water. This was diluted 1/10 by transferring 0.2 ml thereof in 1.8 ml of saline. After mixing this was diluted 1/200 by transferring 1 ml in 199 ml of saline to give a suspension containing approximately 10^4 EID₅₀ per 0.1 ml. Six hundred and fifty embryos of SAN eggs were each inoculated with 0.1 ml of the above virus suspension via the yolk sack route using a 1 ml syringe fitted with a 23 G x 1" needle. The eggs were incubated at 37° C and candled after 24 and 48 hours. Twelve embryos were dead after 24 hours and eleven after 48 hours. These were all discarded. Seventy two hours after inoculation the embryos were removed from the remaining eggs and decapitated. They were pooled into ten groups of approximately 60 embryos. Each group was homogenized separately using an Ystral blender fitted with a small autoclavable shaft. Each homogenate was poured through two layers of gauze over a beaker and each filtrate was transferred to a separate

25

30

Duran bottle. A volume of stabilizer, containing inositol and manitol, equivalent to approximately one third of the volume of the filtrate was added to each. The final volume of each was between 50 and 60 ml. 1 ml was removed from each Duran bottle and pooled. After mixing this was dispensed in 1 ml aliquots into Nunc Cryotubes and these were stored at -70°C for later titration. A further 1 ml aliquot was removed from each Duran bottle and plated individually onto 5 % Blood agar plates to check for sterility. The Duran bottles were all stored at -70°C until

35

Freeze drying and testing of the Working Seed.

40

Each of the Working Seed aliquots were thawed, pooled and mixed well on a magnetic stirrer using a follower. Four hundred and twenty vials were each filled with 1 ml of virus suspension. The vials were placed into the Modulyo freeze drier. Freeze drying was carried out for fourteen hours before the vials were sealed and removed from the Clean Room. Crimp tops were applied to each vial and they were all tested for vacuum using an Edwards spark tester.

The vaccine material itself was prepared from the Working Seed according to the same method as outlined above.

45

EXAMPLE 2

Safety of the vaccine

50

Safety of the vaccine prepared according to EXAMPLE 1 was tested after vaccination of one-day old chickens according to two methods explained below.

Bursa/body weight ratio

55

The bursa size is expressed as the bursa / body weight ratio (BBR) according to the following formula:

$$BBR = \frac{\text{bursa weight (g)} \times 1000}{\text{body weight (g)}}$$

Lesion score of bursa

The lesions seen by microscopical examination are judged as follows:

After weighing, the removed bursae were fixed in 4% formalin for microscopical examination at the PHC, Doorn,
5 The Netherlands. The results were scored as summarized in TABLE 2.

TABLE 2

SCORE	OBSERVATIONS
0	No damage.
1	Some necrosis/lymphodepletion in isolated follicles.
2	Moderate generalized lymphodepletion or severe lymphodepletion in isolated follicles. Some fibrosis, some epithelial proliferation.
3	Over 50% of follicles with severe lymphodepletion. Fibrosis and epithelial proliferation. Some follicles have been replaced by cavities, initially filled with necrotic tissue (approx. 6 days post-infection), later on (after clearance of the necrotic tissue) lined with epithelium.
4	All follicles display severe lymphodepletion; only in their cortex lymphocytes may be discernible. Marked fibrosis and epithelial proliferation. Several follicles have been replaced by the afore-mentioned cavities.
5	Total loss of follicular architecture. Severe fibrosis and epithelial proliferation. The afore-mentioned cavities are scattered throughout the bursal tissue.

Groups of 30 birds each were vaccinated with the 9793 vaccine by spray, except for the controls. Three weeks after vaccination half of the birds of each group were killed and the BBR was determined. The remaining half of the birds of each group were challenged at .3 weeks after vaccination. This challenge was carried out using a highly virulent field strain (D6948E, obtained from the Animal Health Institute at Deventer, The Netherlands). 10-12 days after challenge these birds were sacrificed as well and the BBR was determined. From a selected number of groups both prior to and after challenge the bursa were examined microscopically and the lesion score was determined.

ResultsBBR.

The results of the BBR determinations are summarized in TABLE 3. These results show that the percentile BBR after vaccination as a mean is about 60. Hence, it can be concluded that the damage to the bursa by the vaccine virus is very moderate. Furthermore, it is clear that the effect of the challenge virus to the bursa of vaccinated birds is absent, whereas in the control birds a considerable damage to the bursa is prominent. These latter data from the control birds in fact confirm the data earlier presented for field viruses and virulent vaccine strains.

TABLE 3

trial/group	% BBR	
	3 w. after vaccination	10-12 days post-challenge
1a	46	47
1b	68	56
1c*	100	37
2a	45	55
2b	46	59
2c*	100	38
3a	51	62
3b	93	40
3c*	100	27
mean vaccinated	58.7	52
mean control	100	34.0

* non-vaccinated controls.

Microscopical examination.

The microscopically visible damage to the bursa is summarized in TABLE 4. The lesion score after vaccination is very low and at an acceptable level for a vaccine, whereas a very high score is found in unvaccinated bird after challenge. The bursa of vaccinated birds again showed to be unaffected by the challenge virus.

TABLE 4

trial/group	microscopical score	
	3 w. after vaccination	10 days post-challenge
3a	1.8	1.2
3b	1.5	1.2
3c*	0.6	4.2

* non-vaccinated controls

EXAMPLE 3Seroresponse after vaccination

These studies were carried out with the birds used for EXAMPLE 2. Blood samples of the birds were taken at approximately 5 or 6 days of age. Individual titers 2 - 5 days later were calculated according to the formula of Kouwenhoven (B. Kouwenhoven and J. van den Bosch; in: Proceedings of 19th World's Poultry Congress, 1992, p. 465-468). Birds were divided then over different titer groups and vaccinated. During 3 or 4 weeks, blood samples were taken to examine seroconversion.

Results

The results of these studies are summarized in TABLE 5. These data confirm the high efficacy of the vaccine according to the present invention. High levels of maternal antibodies do not interfere with the vaccination. Kouwenhoven (*supra*) gives ELISA titers of about 500 that intermediate plus strains are able to break through. The vaccine

according to the present invention easily breaks through higher levels of maternal antibodies to induce seroconversion.

TABLE 5

trial/group	calculated titer at day of vacc.	vacc. dose (10^{\log} EID ₅₀)	mean antibody titer to IBD at days p.v.			
			7	14	21	28
1a	122	3.4	2	1061	1560	ND
1b	939	3.4	18	676	1088	ND
1c*	142	-	2	80	134	ND
2a	668	3.7	ND	3	410	1434
2b	649	3.7	ND	83	946	1808
2c*	1054	-	ND	85	3	31
3a	256	3.7	ND	760	2167	ND
3b	2235	3.7	ND	202	737	ND
3c*	1089	-	ND	42	55	ND

* non-vaccinated controls; "ND" means not determined.

Claims

- Vaccine which is capable of protecting poultry against Infectious Bursitis infections, characterized in that it contains an Infectious Bursitis virus which has the combined properties of upon administration to a chicken causing a reduction in the size of the bursal size, expressed as bursa/body weight ratio, of less than 55 % and the capability to protect poultry having an ELISA antibody titer of at least about 500.
- Vaccine according to claim 1, characterized in that the Infectious Bursitis virus is a virus of the strain 9793, a sample of which is deposited at Institut Pasteur at the Collection Nationale de Cultures de Microorganismes under No I-1810.
- Vaccine according to claim 1, characterized in that it contains the virus in an amount of between 10^2 and 10^6 EID₅₀ per dose.
- Vaccine according to claim 1, characterized in that it contains the virus in an amount of between 10^3 and 10^5 EID₅₀ per dose.
- Infectious Bursitis virus characterized by the combined properties of upon administration to a chicken causing a reduction in the size of the bursal size, expressed as bursa/body weight ratio, of less than 55 % and the capability to protect poultry having an ELISA antibody titer of at least about 500.
- Infectious Bursitis virus according to claim 5, characterized in that the Infectious Bursitis virus is a virus of the strain 9793, a sample of which is deposited at Institut Pasteur at the Collection Nationale de Cultures de Microorganismes under No I-1810.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 97 20 0298

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	EP 0 600 723 A (ABIC LTD) 8 June 1994 * page 2, line 49 - page 3, line 44; claims 1,10 *	1,5	A61K39/12 C12N7/08 A61K35/76
Y	---	1,3-5	
X	US 5 192 539 A (VAN DER MAREL PIET ET AL) 9 March 1993 * claims 1-3 *	1,5	
Y	---	1,3-5	
X	US 4 824 668 A (MELCHIOR JR FRED W ET AL) 25 April 1989 * claims 2-24 *	1,5	
Y	---	1,3-5	
A	WORLD'S POULTRY SCIENCE JOURNAL 50 (2). 1994. 133-166. ISSN: 0043-9339, XP002041802 LASHER H N ET AL: "Infectious bursal disease." * see page 149, paragraph Prevention of IBD *		TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A	WO 91 05569 A (UNIV MARYLAND) 2 May 1991 * claims 1-8 *		A61K C12N C07K G01N C12P C12Q
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 25 September 1997	Examiner Halle, F
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background () : non-written disclosure P : intermediate document</p> <p>I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01.82 (P04C01)